Cellectar Biosciences Inc (CLRB)

[Crusader]

No news yet that CRB sold its FDA voucher getting about $125M from another company.

“...Priority review vouchers can be used by the sponsor to receive priority review designation for a future NDA or BLA submission, which could reduce the FDA review time from twelve months to eight months. Currently, these vouchers can also be transferred or sold to another entity. Since the beginning of 2017, six priority review vouchers were sold for between $80 million and $150 million each...”

I would be tempted to do so unless, for example, there were a more profitable alternative use of the voucher in getting a CLR131 platform to market 4 months earlier with FDA BLESSINGS.

Either way we want NO MORE REVERSE COMMON STOCK SHARE SPLITS!